

Supplemental Table S2. Change from Baseline in ALT, AST, Creatinine, and CPK after Pitavastatin Treatment

Variable	No. (%)			
	All (n=28,343)	1 mg (n=146)	2 mg (n=19,292)	4 mg (n=8,802)
ALT, IU/L				
>3×UNL ^a	34 (0.12)	1 (0.68)	23 (0.12)	9 (0.10)
≤3×UNL	28,309 (99.88)	145 (99.32)	19,269 (99.88)	8,793 (99.90)
AST, IU/L				
>3×UNL ^a	49 (0.17)	0	35 (0.18)	10 (0.11)
≤3×UNL	28,294 (99.83)	146 (100.00)	19,257 (99.82)	8,792 (99.89)
Creatinine, mg/dL				
>1.5×UNL ^a	198 (0.70)	0	139 (0.72)	57 (0.65)
≤1.5×UNL	28,145 (99.30)	146 (100.00)	19,153 (99.28)	8,745 (99.35)
CPK, IU/L				
>2.5×UNL ^a	35 (0.12)	3 (2.05)	20 (0.10)	10 (0.11)
≤2.5×UNL	28,308 (99.88)	143 (97.95)	19,272 (99.90)	8,792 (99.89)
>5×UNL	4 (0.01)	0	3 (0.02)	1 (0.01)
≤5×UNL	28,339 (99.99)	146 (100.00)	19,289 (99.98)	8,801 (99.99)

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; UNL, upper normal limit.

^aGrade 2 toxicity in Common Terminology Criteria for Adverse Events v 4.03.